Clinical Trials Directory

Trials / Completed

CompletedNCT00917111

The Effect of Nasal Carbon Dioxide (CO2) in the Symptomatic Treatment of Seasonal Allergic Rhinitis

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Pilot Study to Evaluate the Efficacy and Safety of Nasal Carbon Dioxide Used Four Times a Day in the Symptomatic Treatment of Seasonal Allergic Rhinitis

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
33 (actual)
Sponsor
Capnia, Inc. · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the effect of four times a day treatment with nasal carbon dioxide in patients with Seasonal Allergic Rhinitis symptoms.

Detailed description

This randomized, double-blind, placebo-controlled, multi-center, parallel group, pilot study will evaluate the efficacy and safety of a four times a day treatment with nasal, non-inhaled administration of CO2 (nasal CO2) in patients with SAR. Approximately 50 patients who meet the eligibility criteria will be enrolled into this study at up to 4 sites to ensure that approximately 30 patients complete the study. Patients will be randomized to one of two treatment groups and be provided with either an active or placebo dispenser. All patients will administer study drug for 10 seconds to each nostril once on Day 0 in the clinic then four times a day during waking hours (approximately 4 hours apart) for 14 days. Patients will assess their nasal and non-nasal symptoms in a patient diary. Each patients participation in the study may last up to 72 days. There will be a total of 5 scheduled clinic visits: * Visit 1 Screening * Visit 2 Enrollment (within 42 days of Visit 1) * Visit 3 Randomization (after the completion of a 3-7 day run-in period) * Visit 4 Mid-Treatment (Day 7 ± 1 day) * Visit 5 End of Treatment (within 1-3 days of last study drug administration) Sites will follow-up with randomized patients via telephone 7 ± 1 days after the last study drug administration.

Conditions

Interventions

TypeNameDescription
DRUGNasal CO2Four times a day for 14 days
DRUGInactive Placebo GasPlacebo

Timeline

Start date
2009-07-01
Primary completion
2009-10-01
Completion
2009-11-01
First posted
2009-06-10
Last updated
2012-08-15

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00917111. Inclusion in this directory is not an endorsement.

The Effect of Nasal Carbon Dioxide (CO2) in the Symptomatic Treatment of Seasonal Allergic Rhinitis (NCT00917111) · Clinical Trials Directory